Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
March 20, 2024 07:00 ET | Orchard Therapeutics (Europe) Limited
Five specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist patient services program to provide...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
March 18, 2024 15:41 ET | Orchard Therapeutics (Europe) Limited
TOKYO and LONDON and BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
February 05, 2024 07:00 ET | Orchard Therapeutics (Europe) Limited
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells ...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
February 02, 2024 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
January 25, 2024 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on...
Orchard-New-Logo-102419-v01-rgb.png
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
January 24, 2024 05:00 ET | Orchard Therapeutics (Europe) Limited
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD
December 11, 2023 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the Swiss Agency for Therapeutic Products (Swissmedic) has...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
November 30, 2023 07:00 ET | Orchard Therapeutics (Europe) Limited
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
November 13, 2023 07:00 ET | Orchard Therapeutics (Europe) Limited
Reported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date Planned acquisition by Kyowa Kirin valued at up to $477.6 million with an anticipated closing in the first...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
October 26, 2023 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a range of interim clinical outcomes, in addition to the...